35.95MMarket Cap-1.94P/E (TTM)
1.6000High1.3300Low546.70KVolume1.4000Open1.4000Pre Close822.72KTurnover2.79%Turnover RatioLossP/E (Static)22.90MShares2.119952wk High6.02P/B30.74MFloat Cap0.860052wk Low--Dividend TTM19.58MShs Float13.7500Historical High--Div YieldTTM19.29%Amplitude0.2479Historical Low1.5040Avg Price1Lot Size
Femasys Stock Forum
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
Thursday, 13th March at 8:30 am
ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, anno...
Could This Non-Surgical Birth Control Method Replace Traditional Sterilization? Clinical Trials Say Yes
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
Tuesday, 25th February at 9:20 am
--Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners--
ATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unme...
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
Tuesday, 11th February at 9:00 am
ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the Medicines & Healthcare products R...
Femasys -Israeli Regulatory Approvals for Femaseed for Female Infertility Treatment and Two Diagnostic Devices
Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
Tuesday, 4th February at 9:00 am
ATLANTA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the Israeli Medical Device Divisi...
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
Thursday, 30th January at 8:30 am
ATLANTA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the European Patent Office ("EP...
just
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of Femaseed® for Female Infertility Treatment
Femasys Announces Partnership With Hrc Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer Femaseed
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
No comment yet